About
MEBIAS’ business model is comprised of partnering and advancing its own molecules into early clinical development. Six years since its founding, the company has validated its unique drug discovery, identified a novel preclinical mu-opioid candidate entering Phase 1 human clinical studies in 2022, and currently developing Sphingosine 1-phosphate receptor (S1PR1) agonists for the treatment of neuropathic pain.
Philadelphia